

Michael R Kilbourn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9144333/publications.pdf>

Version: 2024-02-01

26
papers

355
citations

1040056

9
h-index

839539

18
g-index

26
all docs

26
docs citations

26
times ranked

573
citing authors

#	ARTICLE	IF	CITATIONS
1	Positron emission tomography imaging of (2R,3R)-5-[18F]fluoroethoxybenzovesamicol in rat and monkey brain: a radioligand for the vesicular acetylcholine transporter. <i>Nuclear Medicine and Biology</i> , 2009, 36, 489-493.	0.6	55
2	Pharmacokinetics of [18F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain. <i>Nuclear Medicine and Biology</i> , 2007, 34, 233-237.	0.6	45
3	Classics in Neuroimaging: Development of PET Tracers for Imaging Monoamine Oxidases. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1867-1871.	3.5	42
4	Identification of AV-1451 as a Weak, Nonselective Inhibitor of Monoamine Oxidase. <i>ACS Chemical Neuroscience</i> , 2019, 10, 3839-3846.	3.5	37
5	In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations. <i>Nuclear Medicine and Biology</i> , 2010, 37, 3-8.	0.6	33
6	Small Molecule PET Tracers for Transporter Imaging. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 536-552.	4.6	19
7	Classics in Neuroimaging: Radioligands for the Vesicular Monoamine Transporter 2. <i>ACS Chemical Neuroscience</i> , 2019, 10, 25-29.	3.5	14
8	Anesthesia increases in vivo N-([18F]fluoroethyl)piperidinyl benzilate binding to the muscarinic cholinergic receptor. <i>Nuclear Medicine and Biology</i> , 2007, 34, 479-482.	0.6	12
9	PET radioligands for the vesicular transporters for monoamines and acetylcholine. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 167-171.	1.0	11
10	11C- and 18F-Radiotracers for In Vivo Imaging of the Dopamine System: Past, Present and Future. <i>Biomedicines</i> , 2021, 9, 108.	3.2	11
11	Increased in vivo [11C]raclopride binding to brain dopamine receptors in amphetamine-treated rats. <i>European Journal of Pharmacology</i> , 2011, 654, 254-257.	3.5	9
12	Classics in Neuroimaging: Development of Positron Emission Tomography Tracers for Imaging the GABAergic Pathway. <i>ACS Chemical Neuroscience</i> , 2020, 11, 2039-2044.	3.5	9
13	Development of Positron Emission Tomography Radiotracers for the GABA Transporter 1. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2767-2773.	3.5	8
14	Classics in Neuroimaging: Imaging the Cholinergic System with Positron Emission Tomography. <i>ACS Chemical Neuroscience</i> , 2021, 12, 1472-1479.	3.5	7
15	Classics in Neuroimaging: Shedding Light on Opioid Receptors with Positron Emission Tomography Imaging. <i>ACS Chemical Neuroscience</i> , 2020, 11, 2906-2914.	3.5	6
16	Fluorine-for-hydrogen: a strategy for radiolabeling, not a replacement. <i>Nuclear Medicine and Biology</i> , 2013, 40, 956-958.	0.6	5
17	Carbon-11 labeled cathepsin K inhibitors: Syntheses and preliminary in vivo evaluation. <i>Nuclear Medicine and Biology</i> , 2014, 41, 384-389.	0.6	5
18	5-tert-Butyl-2-(4-([18F]fluoropropynylphenyl)-1,3-dithiane oxides: potential new GABAA receptor radioligands. <i>Nuclear Medicine and Biology</i> , 2008, 35, 549-559.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Rat pancreas uptake of [¹¹ C]dihydrotetrabenazine stereoisomers. Nuclear Medicine and Biology, 2010, 37, 869-871.	0.6	4
20	Is logP truly dead?. Nuclear Medicine and Biology, 2017, 54, 41-42.	0.6	4
21	A six-year longitudinal PET study of (+)-[¹¹ C]DTBZ binding to the VMAT2 in monkey brain. Nuclear Medicine and Biology, 2017, 55, 34-37.	0.6	4
22	In vitro binding affinity vs. in vivo site occupancy: A PET study of four diastereomers of dihydrotetrabenazine (DTBZ) in monkey brain. Nuclear Medicine and Biology, 2021, 92, 38-42.	0.6	4
23	Evaluation of Enzyme Substrate Radiotracers as PET/MRS Hybrid Imaging Agents. ACS Medicinal Chemistry Letters, 2018, 9, 1140-1143.	2.8	3
24	Improved Synthesis of [¹¹ C]COU and [¹¹ C]PHXY, Evaluation of Neurotoxicity, and Imaging of MAOs in Rodent Heart. ACS Medicinal Chemistry Letters, 2020, 11, 2300-2304.	2.8	2
25	PET studies in non-human primates: Choosing drug doses. Nuclear Medicine and Biology, 2017, 47, 1-3.	0.6	1
26	Issues in preclinical radiopharmaceutical research: Significance, relevance and reproducibility. Nuclear Medicine and Biology, 2018, 67, 52-55.	0.6	1